These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21359555)

  • 1. [Patient/rheumatologist evaluation of infusion treatment for rheumatoid arthritis].
    Willeke P; Becker H; Wassenberg S; Pavenstädt H; Jacobi AM
    Z Rheumatol; 2011 Apr; 70(3):232-4, 236-8. PubMed ID: 21359555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accelerated infusion rates of rituximab are well tolerated and safe in rheumatology practice: a single-centre experience.
    Can M; Alibaz-Öner F; Yılmaz-Öner S; Atagündüz P; İnanç N; Direskeneli H
    Clin Rheumatol; 2013 Jan; 32(1):87-90. PubMed ID: 23053686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of rheumatoid arthritis in Turkey: a questionnaire study.
    Direskeneli H; Akkoç N; Bes C; Cakir N; Cefle A; Cobankara V; Dalkilic E; Dinc A; Ertenli I; Gul A; Hamuryudan V; Inanc M; Kalyoncu U; Karaaslan Y; Kasifoglu T; Keser G; Keskin G; Kisacik B; Kiraz S; Masatlioglu S; Onat AM; Ozbek S; Ozturk MA; Pamuk ON; Pay S; Pirildar T; Sayarlioglu M; Senel S; Senturk T; Tasan D; Terzioglu E; Yazici A; Yucel E
    Clin Exp Rheumatol; 2014; 32(4):477-83. PubMed ID: 24960289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perceptions of methotrexate use in rheumatoid arthritis by rheumatologists and their patients: an Australian survey study.
    Nash P; Nicholls D
    Int J Rheum Dis; 2013 Dec; 16(6):652-61. PubMed ID: 24382276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis.
    Conti F; Ceccarelli F; Perricone C; Alessandri C; Conti V; Massaro L; Truglia S; Spinelli FR; Spadaro A; Valesini G
    Rheumatology (Oxford); 2011 Jun; 50(6):1148-52. PubMed ID: 21278072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Openness to and preference for attributes of biologic therapy prior to initiation among patients with rheumatoid arthritis: patient and rheumatologist perspectives and implications for decision making.
    Bolge SC; Goren A; Brown D; Ginsberg S; Allen I
    Patient Prefer Adherence; 2016; 10():1079-90. PubMed ID: 27390518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient and physician perception of the infusion process of the biologic agents abatacept, infliximab, and rituximab for the treatment of rheumatoid arthritis.
    Yazici Y; McMorris BJ; Darkow T; Rosenblatt LC
    Clin Exp Rheumatol; 2009; 27(6):907-13. PubMed ID: 20149304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registry.
    De Keyser F; Hoffman I; Durez P; Kaiser MJ; Westhovens R;
    J Rheumatol; 2014 Sep; 41(9):1761-5. PubMed ID: 25128506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register.
    Soliman MM; Hyrich KL; Lunt M; Watson KD; Symmons DP; Ashcroft DM;
    Arthritis Care Res (Hoboken); 2012 Aug; 64(8):1108-15. PubMed ID: 22422731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label study.
    Rigby WF; Mease PJ; Olech E; Ashby M; Tole S
    J Rheumatol; 2013 May; 40(5):599-604. PubMed ID: 23547218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study.
    Pritchard CH; Greenwald MW; Kremer JM; Gaylis NB; Rigby W; Zlotnick S; Chung C; Jaber B; Reiss W;
    BMC Musculoskelet Disord; 2014 May; 15():177. PubMed ID: 24884454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What Matters Most to Patients and Rheumatologists? A Discrete Choice Experiment in Rheumatoid Arthritis.
    Díaz-Torné C; Urruticoechea-Arana A; Ivorra-Cortés J; Díaz S; Dilla T; Sacristán JA; Inciarte-Mundo J; Comellas M; Prades M; Lizán L
    Adv Ther; 2020 Apr; 37(4):1479-1495. PubMed ID: 32088860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective chart review of the use of rituximab for the treatment of rheumatoid arthritis in Australian rheumatology practice.
    Nicholls D; Zochling J; Boers A; Champion G; Mathers D; Riordan J; Youssef P; Scott J; Griffiths H
    Int J Rheum Dis; 2014 Sep; 17(7):755-61. PubMed ID: 24131467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial.
    Shim SC; Božić-Majstorović L; Berrocal Kasay A; El-Khouri EC; Irazoque-Palazuelos F; Cons Molina FF; Medina-Rodriguez FG; Miranda P; Shesternya P; Chavez-Corrales J; Wiland P; Jeka S; Garmish O; Hrycaj P; Fomina N; Park W; Suh CH; Lee SJ; Lee SY; Bae YJ; Yoo DH
    Rheumatology (Oxford); 2019 Dec; 58(12):2193-2202. PubMed ID: 31184752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rheumatoid arthritis patients and rheumatologists approach the decision to escalate care differently: results of a maximum difference scaling experiment.
    van Hulst LT; Kievit W; van Bommel R; van Riel PL; Fraenkel L
    Arthritis Care Res (Hoboken); 2011 Oct; 63(10):1407-14. PubMed ID: 21748861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab in rheumatoid arthritis and the risk of malignancies: report from a French cohort.
    Slimani S; Lukas C; Combe B; Morel J
    Joint Bone Spine; 2011 Oct; 78(5):484-7. PubMed ID: 21196130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What matters to patients and physicians when considering biologic therapy for rheumatoid arthritis.
    Lisicki R; Chu L
    Postgrad Med; 2008 Sep; 120(3):154-60. PubMed ID: 18824833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register.
    Sebastiani M; Anelli MG; Atzeni F; Bazzani C; Farina I; Fedele AL; Favalli EG; Fineschi I; Cino N; Dal Forno I; Gasparini S; Cassarà E; Giardina R; Bruschi E; Addimanda O; Cassone G; Lopriore S; Sarzi-Puttini P; Filippini M; Pignatti F; Gremese E; Biggioggero M; Manganelli S; Amato G; Caimmi C; Salaffi F; Iannone F; Ferri C; Sandri G; Lapadula G; Gorla R; Govoni M; Ferraccioli G; Marchesoni A; Galeazzi M; Foti R; Carletto A; Cantini F; Triolo G; Epis OM; Salvarani C;
    Joint Bone Spine; 2014 Dec; 81(6):508-12. PubMed ID: 25082646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of pediatric rheumatologists' approach to rituximab use: a questionnaire study.
    Sunar Yayla EN; Gezgin Yıldırım D; Adıgüzel Dündar H; Adrovic A; Akbörü EG; Aktay Ayaz N; Aliyev E; Avar Aydın PÖ; Aydın F; Baba Ö; Bağlan E; Bora Makay B; Bozkaya Yücel B; Çakan M; Çelikel E; Demir F; Demir S; Demirkan FG; Ekici Tekin Z; Esmeray Şenol P; Guliyeva V; Güngörer V; İşgüder R; Kalyoncu M; Karadağ ŞG; Kısaoğlu H; Kışla Ekinci RM; Kızıldağ Z; Kurt T; Özdel S; Özdemir Çiçek S; Öztürk K; Polat MC; Sezer M; Sönmez HE; Sözeri B; Şener S; Taşkın SN; Türkuçar S; Ünsal E; Yıldız Ç; Bakkaloğlu SA
    Eur J Pediatr; 2024 Sep; 183(9):3959-3968. PubMed ID: 38926187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial.
    Haraoui B; Bokarewa M; Kallmeyer I; Bykerk VP;
    J Rheumatol; 2011 Dec; 38(12):2548-56. PubMed ID: 21965646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.